180 Life Sciences (ATNF) Revenue & Revenue Breakdown
180 Life Sciences Revenue Highlights
180 Life Sciences Revenue by Period
180 Life Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
180 Life Sciences generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
180 Life Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $166.03K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
180 Life Sciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
180 Life Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PALI | Palisade Bio | $250.00K | - |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| CNSP | CNS Pharmaceuticals | - | - |
| CYTO | Altamira Therapeutics | - | $52.73K |
| ZURA | Zura Bio | - | - |
| ATNF | 180 Life Sciences | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| IMMX | Immix Biopharma | - | - |
| ENVB | Enveric Biosciences | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
| CDIO | Cardio Diagnostics | - | $7.87K |
ATNF Revenue FAQ
What is 180 Life Sciences’s yearly revenue?
180 Life Sciences's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ATNF's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is 180 Life Sciences’s quarterly revenue?
180 Life Sciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ATNF's quarterly revenue for Q4 2023 was $166.03K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is 180 Life Sciences’s revenue growth rate?
180 Life Sciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.